Nictotine business Nerudia to build £11 million site in Liverpool
Nerudia, in partnership with Contraf-Nicorex-Tobacco (CNT) are to build a large manufacturing site in Liverpool; creating as many as 150 jobs.
David Newns and Chris Lords are the businessmen behind one of Britain’s first e-cigarette businesses, CN Creative (now owned by British American Tobacco). Now they’re starting a new company with CNT and opening a site in Speke.
The manufacturing site will focus on the development, production, testing, and regulatory compliance of nicotine products aimed specifically at the fast-growing e-cigarette market and supply brand owners, with Nerudia recently securing their first major manufacturing contract.
Nerudia will invest £11 million in the Speke facility on Physics Road at the Southern Gateway park.
Currently, there is recruitment for 30 jobs, with the expectation of employment for 150 staff by 2018.
Chief executive of Nerudia, David Newns, said:
“Our new facility will offer the expanding market a fully-outsourced, best-in-class nicotine product manufacturing service providing e-liquids and capsule filling, thus enabling e-cigarette companies to focus on their sales and marketing in this rapidly growing sector.
“The growth of the vaporiser market has been a modern phenomenon, but with that growth has come an increasing focus on key areas of product innovation quality and reliability.”
Headquartered in Heilbronn, Germany, Contraf-Nicorex Tobacco are among the world’s largest suppliers of pharmaceutical-purity nicotine. Managing director of partners CNT, Torsten Siemann, said:
“Nerudia is an exciting opportunity for CNT allowing us to expand our integrated supply chain further. In addition to the supply of ultrapure nicotine made in Switzerland, we will be able to support our customers throughout Europe in their quest to comply with the impending EU regulations that will be in force from 2016.”
Words: Peter Cribley